Social Media Ideas for Drug Development

<![CDATA[The Full Path of Drug Development, and Why So Few Drugs Make It: Q&A with Dr. Ying Huang]]>

<![CDATA[The Next Chapter in Metabolic Drug Development]]>

<![CDATA[Where GLP-1 Development May be Headed]]>

From Discovery to Development

The articles in this eBook examine key trends driving this transformation, from AI-enabled discovery and experimental validation to advanced cell, gene, and biologic platforms, and...

FDA launches pilot program to speed up early US drug research

First teased in June and formally announced Tuesday as part of “Operation Trialblazer,” the program will partner drugmakers with research institutions to more quickly bring medicin...

<![CDATA[METiS Enters Collaboration with Eli Lilly for Next-Generation Tissue-Specific LNP Delivery Technologies]]&gt...

A Takeda spinout builds case for its Parkinson’s drug

Cerevance plans to meet with the FDA to “determine next steps” for a new kind of medicine known as solengepras, now that it has Phase 3 data in hand.

ADC Developmentfrom Concept to Clinic

This eBook brings insight on integrated end-to-end solutions for precision engineered therapeutics. The post ADC Developmentfrom Concept to Clinic appeared first on GEN - Genetic E...

HHS kicks off new programs to speed clinical trials as Chinese competition looms

The department is offering funding to teams with innovative proposals as it considers ending the traditional phased clinical trial system.

<![CDATA[The Most Surprising Development in GLP-1s]]>

<![CDATA[MRD Testing Is Becoming the Most Important Tool in Oncology Drug Development: Q&A with Eric Matthews]]&g...

#409 ‒ Inside modern drug development: the science, economics, and regulatory hurdles behind bringing new medicines to p...

“The way this works is… at a very high level, making a new drug that's used by many people takes longer, is more expensive, and takes as many people as building the biggest skyscra...

Centrix and University of Sussex Collaborate to Drive Data-Driven Pharma Development

The KTP provides access to academic expertise while embedding that capability within Centrix’s business. This project represents an opportunity to apply advanced data science techn...

<![CDATA[Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data]]>

Developer acquires global rights to Parkinson’s drug in deal worth $300M

In a deal that could be worth more than $300 million, a Korean biotech has acquired exclusive global rights to develop and commercialize 1ST Biotherapeutics‘ 1ST-104, an oral treat...

AI Drug Discovery Hits a New Bottleneck: Experimental Validation

Sponsored content brought to you by Artificial intelligence is dramatically accelerating early drug discovery. Models can screen chemical space, predict structures, optimize proper...

Designing Peptide Screens to Generate Knowledge, Not Just Hits

The strongest binder from a primary screen is not necessarily the best drug starting point. Peptide discovery campaigns should capture molecular architecture, biological context, t...

Novo partners with Orbis, deepening investment in oral peptide drugs

The potentially $1.4 billion alliance will see the two companies collaborate on “macrocycles” that could yield oral treatments for cardiometabolic diseases.

WCLC 2026: The lung cancer drug development readouts that caught our eye 

Find out what came out of the World Conference on Lung Cancer (WCLC) 2026, from late-stage successes and failures to earlier-stage promise. The post WCLC 2026: The lung cancer drug...

Streamlining stable cell line development from the start

Discover how early optimization in stable cell line development accelerates timelines and reduces downstream bottlenecks. The post Streamlining stable cell line development from th...

Hype vs. reality: What pharma’s hottest R&D bets have actually proved

New types of bispecifics, antibody-drug conjugates and cell therapies haven’t yet proven themselves in the clinic. Pharmaceutical companies are betting billions anyway.

<![CDATA[Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909]]&gt...

<![CDATA[M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to...

<![CDATA[From Direct-to-Patient to Direct-to-Disease: New Commercialization Models in Europe]]>